Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma

Authors

  • N. Patrik Brodin Radiation Medicine Research Center, Department of Radiation Oncology, Rigshospitalet, University of Copenhagen, Denmark; Niels Bohr Institute, Faculty of Sciences, University of Copenhagen, Denmark
  • Per Munck AF Rosenschöld Radiation Medicine Research Center, Department of Radiation Oncology, Rigshospitalet, University of Copenhagen, Denmark
  • Marianne C. Aznar Radiation Medicine Research Center, Department of Radiation Oncology, Rigshospitalet, University of Copenhagen, Denmark
  • Anne Kiil-Berthelsen Radiation Medicine Research Center, Department of Radiation Oncology, Rigshospitalet, University of Copenhagen, Denmark; Department of Clinical Physiology and Nuclear Medicine, Centre of Diagnostic Investigations, Rigshospitalet, University of Copenhagen, Denmark
  • Ivan R. Vogelius Radiation Medicine Research Center, Department of Radiation Oncology, Rigshospitalet, University of Copenhagen, Denmark
  • Per Nilsson Department of Oncology, Skåne University Hospital and Lund University, Lund, Sweden
  • Birgitta Lannering Department of Paediatric Oncology, The Queen Silvia Children's Hospital, Gothenburg, Sweden
  • Thomas Björk-Eriksson Department of Oncology, Skåne University Hospital and Lund University, Lund, Sweden

DOI:

https://doi.org/10.3109/0284186X.2011.582514

Abstract

Introduction. The aim of this model study was to estimate and compare the risk of radiation-induced adverse late effects in pediatric patients with medulloblastoma (MB) treated with either three-dimensional conformal radiotherapy (3D CRT), inversely-optimized arc therapy (RapidArc® (RA)) or spot-scanned intensity-modulated proton therapy (IMPT). The aim was also to find dose-volume toxicity parameters relevant to children undergoing RT to be used in the inverse planning of RA and IMPT, and to use in the risk estimations. Material and methods. Treatment plans were created for all three techniques on 10 pediatric patients that have been treated with craniospinal irradiation (CSI) at our institution in 2007–2009. Plans were generated for two prescription CSI doses, 23.4 Gy and 36 Gy. Risk estimates were based on childhood cancer survivor data when available and secondary cancer (SC) risks were estimated as a function of age at exposure and attained age according to the organ-equivalent dose (OED) concept. Results. Estimates of SC risk was higher for the RA plans and differentiable from the estimates for 3D CRT at attained ages above 40 years. The risk of developing heart failure, hearing loss, hypothyroidism and xerostomia was highest for the 3D CRT plans. The risks of all adverse effects were estimated as lowest for the IMPT plans, even when including secondary neutron (SN) irradiation with high values of the neutron radiation weighting factors (WRneutron). Conclusions. When comparing RA and 3D CRT treatment for pediatric MB it is a matter of comparing higher SC risk against higher risks of non-cancer adverse events. Considering time until onset of the different complications is necessary to fully assess patient benefit in such a comparison. The IMPT plans, including SN dose contribution, compared favorably to the photon techniques in terms of all radiobiological risk estimates.

Downloads

Download data is not yet available.

Downloads

Published

2011-08-01

How to Cite

Patrik Brodin, N., AF Rosenschöld, P. M., Aznar, M. C., Kiil-Berthelsen, A., Vogelius, I. R., Nilsson, P., … Björk-Eriksson, T. (2011). Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncologica, 50(6), 806–816. https://doi.org/10.3109/0284186X.2011.582514

Issue

Vol. 50 No. 6 (2011): Acta Oncologica

Section

Articles